Trial Profile
A double-blind placebo-controlled study of the safety, tolerability and efficacy of 12 months' treatment with ACI 91 in patients with mild to moderate Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2013
Price :
$35
*
At a glance
- Drugs Pirenzepine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors AC Immune
- 14 Mar 2012 Planned number of patients changed from 60 to 64 as reported by EudraCT (Germany).
- 14 Mar 2012 Additional trial locations (Austria, Germany) identified as reported by EudraCT.
- 27 May 2011 Planned End Date changed to 1 Mar 2012.